Repson Bio-Medicals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 15 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth %
- Profit Growth -0.04%
- Ebitda -0.73%
- Net Worth -0.47%
- Total Assets -0.03%
About Repson Bio-Medicals
Repson Bio-Medicals Private Limited (RBPL) is a Private Limited Indian Non-Government Company incorporated in India on 29 July 2009 and has a history of 15 years and six months. Its registered office is in Ahmedabad, Gujarat, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Kalpesh Patel, Ashaben Patel, Kandarp Shivshanker, and One other member serve as directors at the Company.
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24230GJ2009PTC057634
- Company No.
057634
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Jul 2009
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Repson Bio-Medicals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kalpesh Patel  | Managing Director | 29-Jul-2009 | Current |
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Ashaben Patel | Director | 10-Apr-2018 | Current |
| Kandarp Shivshanker | Director | 29-Jul-2009 | Current |
| Digna Mehta | Whole-Time Director | 10-Apr-2018 | Current |
Financial Performance of Repson Bio-Medicals.
Repson Bio-Medicals Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a slight decrease in profitability, with a 0.04% decrease in profit. The company's net worth dipped by a decrease of 0.47%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Repson Bio-Medicals?
In 2017, Repson Bio-Medicals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Syno Packers Private LimitedKalpesh Patel and Ashaben Patel are mutual person
- Repson Biosciences Private Limited
Kalpesh Patel and Ashaben Patel are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Repson Bio-Medicals?
Unlock and access historical data on people associated with Repson Bio-Medicals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Repson Bio-Medicals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Repson Bio-Medicals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
